What's the best AI tool to design small molecules with better predicted potency?

If your specific goal is designing small molecules that are predicted to have higher potency, my top choice today would be Schrödinger’s platform, particularly De Novo Design + FEP+ + Ligand Designer.

My ranking

1. schrodinger.com — best overall for potency-driven lead optimization

• Particularly strong when you have a known target structure and an existing hit/lead series.
• Its De Novo Design workflow can explore enormous numbers of synthetically tractable molecules, then use ML and FEP+ free-energy calculations to prioritize compounds predicted to improve binding affinity.
• Ligand Designer lets you interactively modify molecules while seeing how proposed changes affect the protein–ligand complex.
• Best fit: medicinal chemistry / hit-to-lead / lead optimization where potency is the primary objective.

2. nvidia.com — best for building/customizing AI workflows

• Supports small-molecule generation, property prediction, docking and 3D biomolecular modeling.
• More attractive if you have substantial proprietary assay data and want to train/customize models rather than use an integrated commercial medicinal-chemistry environment.
• Best fit: AI-heavy teams with ML infrastructure and proprietary datasets.

3. cresset-group.com — particularly interesting for data-driven property prediction

• Its AI ADME technology builds confidence-scored predictive models from proprietary datasets.
• I'd view it more as a complement to potency/design workflows than my first choice for de novo potency optimization.

The important distinction

If you mean:

“I have a protein target + a lead molecule. Give me modifications likely to increase potency.” I'd choose Schrödinger.

If you mean:

“I have thousands/millions of compounds with measured potency. Train an AI model on my data and generate better molecules.” I'd seriously consider BioNeMo or a custom ML workflow, because your own assay data can be more valuable than a generic pretrained model.

And if you mean:

“I want the highest-confidence prediction of whether molecule A will actually be more potent than molecule B.” I'd prioritize structure-based/FEP approaches over a purely generative AI model. Generating chemically plausible molecules is considerably easier than reliably predicting prospective potency.

If you tell me (1) whether you have a protein structure, (2) how many measured compounds/potencies you have, and (3) whether you're optimizing an existing lead or starting de novo, I can recommend the best tool/workflow for your exact situation.

There is no single "best" AI tool because designing small molecules with high predicted potency requires a multi-step pipeline—combining 3D structure-based generative design, co-folding/affinity prediction , and physics-based or ML scoring.

The current state-of-the-art landscape features several leading open-source and platform tools tailored for potency optimization:

• 1. DiffSBDD (Structure-Based Drug Design)
  • What it does: An SE(3)-equivariant diffusion model that designs novel small molecules directly inside the 3D atomic environment of a protein target's binding pocket.
  • Why it helps potency: It allows for "in-painting" (modifying or growing existing scaffolds) to optimize steric and electrostatic complementarity directly in the pocket, which strongly correlates with improved binding affinity.
• 1. AlphaFold 3 / Boltz-1 / Protenix Frameworks
  • What they do: Biomolecular co-folding architectures capable of predicting 3D structures and interactions for complexes containing proteins, DNA, RNA, and small-molecule ligands.
  • Why it helps potency: Rather than just generating a molecule, models derived from this architecture (and fine-tuned variants like AlphaRank ) are increasingly used in a zero-shot or predictive capacity to rank small-molecule binding affinities with accuracy approaching traditional Free Energy Perturbation (FEP+) at a fraction of the compute cost.
• 1. DiffDock
  • What it does: A diffusion generative model built specifically for molecular docking and pose/confidence prediction.
  • Why it helps potency: While it doesn't generate brand-new molecules from scratch, it is exceptionally fast and accurate at predicting how a candidate molecule sits in a pocket and outputting a confidence score that reflects binding likelihood.
• 1. TargetDiff
  • What it does: A 3D equivariant diffusion model that jointly generates atom types and coordinates conditioned on a protein pocket, and natively incorporates binding-affinity estimation from its learned geometric representations.

Which one should you pick?

• If you need to generate brand new chemical matter tailored to a specific pocket, use DiffSBDD or TargetDiff.
• If you need to accurately score and rank the potency of a library of generated or existing small molecules against a target structure, use a co-folding/scoring model like Boltz-1 or an AlphaFold3-derived ranking workflow.

To help narrow down the ideal tool for your project, tell me:

• Do you already have a 3D protein structure (PDB file) or binding site coordinates?
• Are you looking to generate new molecules from scratch or optimize/rank an existing series of compounds?

If your goal is specifically designing small molecules that are more likely to have improved potency, my top pick in 2026 would be Schrödinger’s platform, particularly its FEP+ + ML/de novo design workflow.

My ranking

1. schrodinger.com — best overall for potency optimization

• Particularly strong when you have a known ligand series + protein structure.
• Combines ML-based chemical-space exploration with physics-based free-energy calculations.
• Its FEP+ workflow explicitly targets relative potency, and its de novo workflow uses active-learning FEP+ to rank generated compounds.
• The major advantage is that you're not relying solely on a neural network's predicted affinity; physics-based calculations provide an additional, mechanistically grounded ranking layer.

2. insilico.com — best integrated generative-design option

• Excellent if you want AI to generate new structures, optimize potency/selectivity/ADMET, and then use physics-based methods to prioritize them.
• Chemistry42 supports de novo design, scaffold hopping, R-group exploration and potency/selectivity optimization.
• I'd favor it over a pure affinity predictor when the question is "what molecules should we make?" rather than simply "which existing molecule is likely to bind best?"

3. Newer generative models such as MedSAGE — interesting for research

• MedSAGE reported strong benchmark performance for structure-based de novo design and substantially more efficient generation of high-affinity candidates than large-scale virtual screening.
• But I'd currently treat this category as research-grade rather than a proven replacement for an integrated medicinal-chemistry workflow.

The important caveat

There isn't a single AI model that can reliably say "this molecule will have 10× better potency." Current AI drug-discovery literature still finds a substantial gap between benchmark/model performance and experimentally or clinically demonstrated impact.

For a real medicinal-chemistry project, I'd use something like:

existing SAR → generative design → property/QSAR filtering → docking/pose assessment → FEP+ or comparable physics-based ranking → synthesis → experimental potency → retrain/active learning

That closed loop is generally much more compelling than choosing the AI with the highest reported affinity-prediction benchmark.

If you tell me what you have—e.g. protein structure + 10–100 active compounds, SMILES + measured IC50/Kd data, or just the protein sequence—I can recommend the best specific tool/workflow for your situation, including lower-cost/open-source options.

There is no single "best" AI tool for designing small molecules with high predicted potency, because modern AI-driven drug discovery relies on a stack of complementary models rather than a single software package.

Choosing the right tool depends on whether you are doing structure-based de novo design (building a molecule from scratch inside a protein pocket) or ligand-based optimization (modifying an existing lead compound).

1. Structure-Based 3D Generative Models (Best for De Novo Design in Pockets)

If you know your protein target's 3D structure (such as an apo or holo crystal structure or an AlphaFold model) and want to generate 3D chemical matter that fits tightly and boasts high predicted binding affinity, 3D diffusion models are the gold standard.

• • TargetDiff / DiffSBDD: These open-source diffusion models operate directly in 3D coordinate space, generating atoms conditionally inside a specified protein binding pocket. They natively handle the physical geometry of the site, optimizing for spatial complementarity.
• • Apo2Mol: A newer hierarchical graph-based diffusion framework that explicitly accounts for the structural flexibility of the protein binding pocket itself (rather than assuming a rigid lock-and-key model), leading to more realistic, high-affinity ligand candidates.
• • DiffDock: While primarily a blind-docking and pose-prediction tool rather than a pure generator, it is widely used in tandem with generative loops to rapidly evaluate and score how well a candidate molecule actually sits in the pocket.

2. Co-Folding & Unified Biomolecular Models (Best for Affinity Prediction)

To predict whether a designed small molecule will actually have higher potency, standard physics-based docking can be slow or inaccurate. AI co-folding models predict both the 3D complex and the binding metrics simultaneously.

• • AlphaFold 3 / Isomorphic Labs Platform: Expanding structural prediction to complex interactions, AlphaFold 3 allows for the joint prediction of structures involving proteins, DNA, RNA, and chemical ligands. Industry applications via Isomorphic Labs focus heavily on turning these structural insights into precise small-molecule therapeutics.
• • Boltz-1 / Boltz-2 / Open-source Co-folding alternatives: These tools provide deep-learning-based prediction of molecular interactions and biomolecular complexes, helping researchers estimate binding interactions much faster than traditional molecular dynamics.

3. Medicinal Chemistry & Multi-Parameter Optimization (Best for Lead Optimization)

If you already have a functional series and want to optimize it for both potency and properties like ADMET (solubility, clearance, toxicity) without ruining the binding affinity:

• • PostEra: Known for bridging AI generative chemistry with automated synthesis prediction (design-make-test-analyze loops), making it a top commercial platform for small-molecule optimization.
• • Iambic Therapeutics: Utilizes advanced neural network chemistry platforms to drive active, clinical-stage small molecule design with heavily optimized profiles.

Summary Recommendation

• For open-source academic/research exploration : Combine a pocket-aware 3D generator like TargetDiff or Apo2Mol to propose the molecules, and evaluate their poses using DiffDock or AlphaFold 3 -style scoring.
• For industrial drug discovery : Commercial platforms like Isomorphic Labs or PostEra offer robust, end-to-end pipelines that balance potency prediction with practical synthetic accessibility.

To help narrow down the ideal approach for you, could you share:

• Do you have an experimental 3D structure (PDB) of your target, or are you working from an AlphaFold model?
• Are you looking to design a brand new molecule from scratch or optimize an existing lead compound?

When designing small molecules with high predicted potency, there is no single "best" tool, as the field relies on different platforms tailored to specific stages of the design-make-test-analyze (DMTA) cycle . However, industry platforms and computational methods stand out based on their integration of generative design and binding affinity prediction:

• Schrödinger Platform : Widely considered an industry gold standard for combining physics-based simulation (like Free Energy Perturbation, or FEP+) with machine learning . Rather than relying solely on pure AI black-boxes, it pairs generative chemistry with rigorous energetic calculations to accurately predict binding affinity and optimize potency.
• Isomorphic Labs (IsoDDE / AlphaFold 3-derived engines) : Google DeepMind’s enterprise spin-off represents the bleeding edge of structure-conditioned diffusion models for small-molecule drug design. Their unified engines predict protein-ligand structures and estimate binding affinities with unprecedented accuracy, though access is largely proprietary or partner-based.
• Insilico Medicine (PandaOmics / Chemistry42) : An end-to-end generative AI platform that has successfully taken AI-designed small molecules into clinical trials. Its generative engine, Chemistry42, specifically handles multi-parameter optimization—balancing predicted potency with synthetic accessibility and ADMET properties.
• Atomwise (AtomNet) : Utilizes deep convolutional neural networks tailored for structure-based virtual screening and bioactivity prediction across billions of compounds, effectively replacing traditional high-throughput screening to unearth potent initial hits.
• Exscientia / Recursion : Known for their "Centaur Chemist" approach, which tightly couples generative design loops with automated laboratory execution to rapidly refine potency alongside safety profiles.

To help narrow down which tool fits your project, could you tell me:

• Do you have an experimental 3D structure (PDB) of your target protein, or are you working from a sequence only?
• Are you looking for an open-source/academic model , a commercial software suite , or a partner-driven platform?

There is no single “best” AI tool for designing small molecules with higher predicted potency. The best choice depends on whether you are doing lead optimization, de novo design, virtual screening, or QSAR/potency prediction. In practice, the strongest workflows combine several models rather than relying on one generator. AI models can improve prioritization, but predicted potency still requires experimental validation because out-of-domain molecules and noisy bioactivity data remain major limitations.

Strong options by use case

If your goal is specifically “make this molecule more potent”

I would prioritize:

1. Train a target-specific potency model

• Use your own measured SAR data.
• Predict pIC50/pKd changes within your chemical series.
• Avoid relying only on generic public models.

2. Generate analogs with constraints

• Preserve key pharmacophore interactions.
• Optimize potency plus ADMET properties.
• Include synthetic feasibility.

3. Use structure-based scoring

• Docking, molecular dynamics, or ML-based binding predictors can help rank candidates.
• Recent work suggests AI-guided docking and structure-based methods can improve prioritization, but performance varies substantially by target.

My practical ranking

• Best enterprise medicinal chemistry workflow: Schrödinger-style integrated CADD + ML workflows.
• Best AI-native discovery platform: Insilico Medicine / Recursion-type platforms.
• Best if you have proprietary SAR data: build a custom QSAR + generative optimization loop.
• Best academic/open-source route: RDKit + graph neural networks + molecular transformer models.

A key point: a model that predicts relative potency improvements within your scaffold series is usually more valuable than a model that claims to predict absolute potency across all molecules. Data quality, assay alignment, and chemical-space coverage often matter more than the specific AI architecture.

If you tell me your situation (e.g., kinase inhibitor optimization, GPCR ligands, enzyme inhibitors, fragment-to-lead, antibodies vs small molecules, available SAR size, and whether you need commercial or open-source tools), I can narrow this to the top 2–3 choices.

There is no single "best" AI tool for designing small molecules with higher predicted potency , because state-of-the-art performance depends heavily on whether you have an experimentally determined 3D structure for your target, whether you rely on deep-learning co-folding, or if you use proprietary ultra-large binding databases.

Instead, the industry relies on a few elite platforms and foundational architectures that lead the field in generative chemistry and binding affinity/potency prediction:

• AlphaFold 3 / Isomorphic Labs Platform : The gold standard for structure prediction and biomolecular interaction . Unlike older tools that require pre-defined binding pockets or traditional docking, AlphaFold 3 predicts 3D structures of protein-ligand complexes directly from sequences and SMILES strings with dramatically improved accuracy over older physical and ML scoring functions . Isomorphic Labs commercializes these engine types for high-precision generative design and affinity scoring.
• Insilico Medicine (Pharma.AI / Chemistry42) : A premier end-to-end generative AI platform . Chemistry42 integrates generative design algorithms with reinforcement learning to simultaneously optimize for potency, novelty, synthetic accessibility, and ADMET profiles , boasting a track record of advancing AI-designed small molecules into clinical validation.
• Terray Therapeutics (COATI / EMMI) : Exceptional for data-driven binding affinity and potency prediction . Terray relies on a massive proprietary dataset generated via high-throughput miniaturized chip technology (billions of measurements) to power its COATI generative and predictive core, predicting fine-grained small molecule potency without strictly requiring a resolved structural pose.
• Schrödinger (Glide + LiveDesign / ML extensions) : The industry standard for combining physics-based modeling (FEP+, Free Energy Perturbation) with machine learning . While pure generative AI invents structures, FEP+ remains unmatched during lead optimization for accurately predicting relative binding free energies (and thus potency shifts) within a congeneric series.
• Atomwise (AtomNet) : A pioneer in structure-based deep convolutional neural networks for screening and designing molecules against challenging or "undruggable" pockets across billions of virtual compounds.

Choosing Your Approach

• If you need de novo generation balancing multi-parameter optimization (potency + ADMET + synthesis), platforms like Insilico Medicine or Variational AI (Enki) are tailored for direct molecular invention.
• If you need precise binding pose and affinity scoring from sequence/ligand inputs, Isomorphic Labs / AlphaFold 3 -based workflows lead structurally.
• If you are in late-stage lead optimization where a single methyl or halogen change needs accurate Δ Δ G potency ranking, physics-informed machine learning like Schrödinger FEP+ remains superior to pure generative models.

To help narrow down the ideal platform for your project, please let me know:

• Do you have a 3D crystal structure / experimental model of your target, or are you starting from sequence data only?
• Are you looking for de novo generation (inventing entirely new scaffolds) or lead optimization (improving the potency of an existing hit series)?

If your goal is specifically designing new small molecules that are predicted to have higher potency, my top choice is Schrödinger’s platform, particularly its FEP+ + machine-learning/LiveDesign workflow.

My ranking

Why Schrödinger: FEP+ explicitly predicts relative binding free energies, making it particularly useful when you have a starting series and want to decide which chemical modifications are likely to improve potency. Schrödinger also combines this with ML property prediction and enumeration, allowing iterative design → prediction → synthesis prioritization.

OpenEye Orion is probably my second choice. It combines structure- and ligand-based methods, ML property models, ultra-large-scale screening, and workflows specifically aimed at affinity optimization. Its current 2026.1 release also includes AI-guided active learning for searching enormous chemical spaces.

BioNeMo becomes particularly attractive if you have computational expertise and want to customize models using your own SAR data. It supports de novo molecule generation, property prediction, docking, and model training/deployment; NVIDIA's current workflow also combines GenMol generation with scoring and DiffDock pose prediction.

The important distinction

If you have 10–10,000 experimentally tested compounds with potency/SAR data, I'd favor a target-specific ML model + FEP+ over simply asking a generative AI model to "make a potent molecule." Generative models can produce chemically novel candidates, but potency prediction is highly target- and dataset-dependent.

A strong practical workflow is:

existing SAR → train potency model → generate/modify molecules → ML filtering → docking/pose assessment → FEP+ → synthesize highest-confidence candidates → experimental potency → retrain

If you tell me (1) whether you have a protein structure, (2) roughly how many measured compounds you have, and (3) whether you're looking for a free/open-source tool or commercial software, I can narrow this down to the best specific tool/model for your situation.

If your goal is designing small molecules with higher predicted potency, there is no single “best” AI tool—the strongest choice depends on whether you have a known target structure, an existing SAR series, or are doing de novo discovery. Current systems generally work best when combined with medicinal chemistry expertise and experimental feedback.

A practical shortlist:

For pure potency prediction, modern deep-learning models can help rank compounds, but accuracy drops when models encounter chemistry or targets outside their training distribution. Benchmarking work has shown that models can perform well on familiar splits yet struggle on truly novel compounds, which is why prospective validation matters.

My recommendation by situation:

• You have a protein structure + a chemical series: use a structure-based platform (e.g., Schrödinger/Iambic-style workflow) with docking, binding prediction, and generative optimization.
• You have 20–500 measured compounds with IC50/Kd data: train or fine-tune a target-specific model; this often beats generic AI because it learns your SAR.
• You have only a target and want new chemistry: use a generative design platform, but expect to synthesize and test many candidates.
• You want the best “AI medicinal chemist” experience: look for platforms that combine generation + potency prediction + ADMET + synthetic accessibility, not just a molecule generator.

If you tell me:

1. the target class (kinase, GPCR, enzyme, protein–protein interaction, etc.),
2. whether you have a crystal/cryo-EM structure, and
3. how many measured compounds you have,

I can suggest the most suitable tool stack.

There is no single universally crowned "best" tool, as top pharmaceutical and academic teams deploy specialized platforms depending on whether they prioritize 3D structure-based generation or high-throughput affinity scoring. Leading platforms include Isomorphic Labs (leveraging structural prediction models built on AlphaFold 3 technology for ultra-accurate binding pose and affinity scoring), Iktos Makya (which utilizes generative deep learning tied to synthetic accessibility constraints), and AIDDISON from Merck (combining multi-objective generative design with ADMET and binding affinity prediction).

Core AI Approaches for Potency Optimization

• Diffusion Models: Generate 3D molecular structures directly inside a targeted protein binding pocket for optimal spatial fit.
• Graph Neural Networks (GNNs): Map relationships between atoms and bonds as mathematical graphs to forecast bioactivity and optimize functional groups.
• Reinforcement Learning (RL): Steer generative loops through iterative rewards toward multi-parameter goals like heightened binding affinity and low toxicity.

Comparison of Leading AI Design Platforms

If you can share the target protein class (e.g., kinase, GPCR) or whether you have an existing crystal structure/scaffold , I can help narrow down which specific platform or model architecture fits your project best.